Biological Safety Testing Products and Services Market Strengthens Labs

The global biological safety testing products & services market size was estimated at USD 4.89 billion in 2024 and is projected to reach USD 12.09 billion by 2033, expanding at a CAGR of 10.64% from 2025 to 2033. The increasing prevalence of target diseases, coupled with the rising production of next-generation biologics by biotechnology and pharmaceutical companies, continues to propel market growth. These factors are strengthening the demand for reliable, accurate, and scalable biosafety testing solutions across the industry.

Key Market Trends & Insights

  • North America accounted for the largest market share, representing 36.59% of the global market in 2024.
  • The U.S. market is expected to observe robust growth throughout the forecast period.
  • By product, the reagents & kits segment dominated with a 39.69% market share in 2024.
  • Based on application, the vaccines & therapeutics segment held the highest share in 2024.
  • By test type, endotoxin tests represented the largest share in 2024.

Market Size & Forecast

  • 2024 Market Size: USD 4.89 Billion
  • 2033 Projected Market Size: USD 12.09 Billion
  • CAGR (2025–2033): 10.64%
  • 2024 Regional Leader: North America

The growing demand for biologics has led to a significant rise in the number of biopharmaceutical manufacturers, driving market expansion. Heightened competition to produce high-quality therapeutic drugs efficiently has encouraged companies to optimize production processes for greater cost-effectiveness and productivity. For example, in July 2023, Biocon Biologics launched a biosimilar version of Humira in the U.S. market at a reduced cost, improving accessibility for patients. This trend highlights the industry’s push toward enhanced manufacturing practices that involve rigorous biological safety testing at multiple stages of production.

The continuous advancement of the biopharmaceutical and biotechnology industries remains a primary growth driver. Increasing development of biologics, biosimilars, cell and gene therapies, and regenerative medicines has heightened the need for validated, standardized, and high-precision biosafety testing. As regulatory standards become more comprehensive globally, companies are ramping up investments in testing infrastructure, innovative technology platforms, and strategic partnerships to address evolving biosafety requirements.

Government initiatives also play a pivotal role in accelerating market growth. For instance, Pfizer and BioNTech’s 2022 collaboration with the U.S. Government to supply additional COVID-19 vaccines underscores the rising governmental support for enhanced biosafety practices. Such efforts are expected to strengthen overall safety protocols in response to growing concerns related to microbial contamination and bioburden in biologics and pharmaceutical production.

Order a free sample PDF of the Biological Safety Testing Products And Services Market Intelligence Study, published by Grand View Research.

Key Biological Safety Testing Products & Services Company Insights

Leading market players are heavily investing in R&D to develop advanced, cost-efficient testing technologies. Strategic initiatives, including acquisitions and partnerships, are further expanding their market footprint. For example, in January 2023, Charles River Laboratories, Inc. acquired SAMDI Tech, Inc., enhancing its high-throughput screening capabilities and reinforcing its position in drug discovery and development services.

Key Biological Safety Testing Products & Services Companies

  • Charles River Laboratories
  • BSL Bioservice
  • Merck KGaA (MilliporeSigma)
  • Samsung Biologics
  • Sartorius AG
  • Eurofins Scientific
  • SGS Société Générale de Surveillance SA
  • Thermo Fisher Scientific Inc.
  • BIOMÉRIEUX
  • Lonza

Conclusion

The biological safety testing products & services market is witnessing strong and sustained growth driven by expanding biologics development, rising regulatory demands, increasing government support, and continuous advancements in testing technologies. As pharmaceutical and biotechnology companies intensify their focus on safety, quality, and compliance, the need for robust biosafety testing will continue to rise. This positions the market for significant opportunities over the coming decade, with both established leaders and emerging players contributing to the sector’s rapid evolution.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Urodynamic Equipment and Consumables Market Forecast: Anticipating Future Innovations

  The global urodynamic equipment and consumables market size is expected to reach USD 449.2 million in 2030 and is projected to grow at a CAGR of 5.7% from 2024 to 2030. This market is anticipated to grow at an unprecedented rate owing to growing geriatric population that exhibits greater vulnerability to urological dysfunctions. In addition, unprecedented upsurge in prevalence of bladder cancer poses high clinical urgency to adopt highly efficient diagnostics, which thereby broadens future growth prospects. In 2017, as per the American Cancer Society, bladder cancer accounted for 5.0% of all cancers in the U.S. The market is also driven by global increase in obesity. As per the Centers for Disease Control and Prevention, approximately 36.0% of adult population is obese. According to a research published in NCBI, obesity has increased the risk of developing various urological conditions, such as prostate cancer, nephrolithiasis, hypogonadism, and urinary tract infections. Furtherm...
Read more

Mobile Device Management Market Thrives with Growth in Cloud-Based Solutions

  According to a recent report by Grand View Research, Inc., the global   mobile device management (MDM) market   is projected to reach USD 28.37 billion by 2030, expanding at a CAGR of 24.5% from 2025 to 2030. This growth is primarily attributed to the increasing use of mobile devices in the workplace and the growing need to manage and secure them effectively. As smartphones, tablets, and other mobile devices become more prevalent, employees are increasingly using their personal devices for work—an approach known as Bring Your Own Device (BYOD). This trend is contributing to the rising number of mobile devices requiring centralized oversight and protection. MDM solutions offer organizations a unified platform to oversee and secure mobile devices, enabling functions such as security policy enforcement, device usage monitoring, and remote data wiping in cases of loss or theft. As companies continue to implement BYOD strategies or issue corporate devices to employees, deman...
Read more

U.S. Interventional Oncology Market Boosted by Aging Population

  The   U.S. interventional oncology market   size was estimated at USD 998.4 million in 2024 and is projected to reach USD 1,597 million by 2030, expanding at a CAGR of 8.17% from 2025 to 2030. This market growth is primarily driven by the increasing prevalence of cancer, continuous technological advancements in minimally invasive treatments, expanding investments in interventional oncology, and the aging population across the U.S. A major contributing factor is the rising incidence of cancer in the country. According to the American Cancer Society, approximately 2,041,910 new cancer cases are expected to be diagnosed in the U.S. in 2025, with 618,120 projected cancer-related deaths. As conventional therapies like chemotherapy and radiation often lead to significant side effects, minimally invasive techniques such as radiofrequency ablation and microwave ablation are becoming more popular. These procedures target tumors precisely while minimizing harm to surrounding tiss...
Read more